LUCD Stock Analysis
LU
Uncovered
Lucid Diagnostics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The company is also developing EsoCure, which is an esophageal ablation device to treat dysplastic barretts esophagus (BE) before it can progress to EAC.